Carisma Therapeutics Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Carisma Therapeutics Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $406.0K | Apr 2, 2018 |
| FY2017 | Dec 31, 2015 | $490.0K | Apr 2, 2018 |
| FY2014 | Dec 31, 2014 | $375.0K | Mar 6, 2015 |
| FY2014 | Sep 30, 2014 | $539.0K | Mar 6, 2015 |
| FY2014 | Jun 30, 2014 | $761.0K | Mar 6, 2015 |
| FY2014 | Mar 31, 2014 | $568.0K | Mar 6, 2015 |
| FY2014 | Dec 31, 2013 | $510.0K | Mar 6, 2015 |
| FY2014 | Sep 30, 2013 | $622.0K | Mar 6, 2015 |
| FY2014 | Jun 30, 2013 | $202.0K | Mar 6, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $19.60M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $14.90M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $9.80M | Apr 1, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Apr 2, 2018 |
| FY2017 | Sep 30, 2017 | $0 | Apr 2, 2018 |
| FY2017 | Jun 30, 2017 | $0 | Apr 2, 2018 |
| FY2017 | Mar 31, 2017 | $425.0K | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $825.0K | Apr 2, 2018 |
| FY2017 | Sep 30, 2016 | $28.65M | Apr 2, 2018 |
| FY2017 | Jun 30, 2016 | $277.0K | Apr 2, 2018 |
| FY2017 | Mar 31, 2016 | $229.0K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $565.0K | Mar 24, 2017 |
| FY2016 | Sep 30, 2015 | $67.0K | Mar 24, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($60.48M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($86.88M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($61.23M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($336.0K) | Feb 28, 2023 |
| FY2022 | Dec 31, 2020 | ($22.40M) | Feb 28, 2023 |
| FY2019 | Dec 31, 2019 | ($33.55M) | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | ($13.13M) | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | ($54.34M) | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | ($6.48M) | Mar 16, 2020 |
| FY2019 | Dec 31, 2018 | ($6.76M) | Mar 16, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($62.18M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($88.73M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($56.16M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($8.55M) | Feb 28, 2023 |
| FY2022 | Dec 31, 2020 | ($21.08M) | Feb 28, 2023 |
| FY2019 | Dec 31, 2019 | ($33.74M) | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | ($13.45M) | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | ($54.56M) | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | ($6.74M) | Mar 16, 2020 |
| FY2019 | Dec 31, 2018 | ($7.07M) | Mar 16, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $59.67M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $74.13M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $56.62M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $25.31M | Feb 28, 2023 |
| FY2022 | Dec 31, 2020 | $29.19M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $24.66M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $14.08M | Mar 15, 2021 |
| FY2019 | Dec 31, 2017 | $12.51M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $13.48M | Mar 1, 2019 |
| FY2017 | Dec 31, 2015 | $26.34M | Apr 2, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($59.92M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($81.18M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($5.12M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($68.88M) | Feb 28, 2023 |
| FY2022 | Dec 31, 2020 | ($30.84M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($37.52M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($22.83M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2017 | ($17.77M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $2.54M | Mar 1, 2019 |
| FY2017 | Dec 31, 2015 | ($34.53M) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $123.0K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $1.13M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.66M | Apr 1, 2024 |
| FY2021 | Dec 31, 2021 | $4.0K | Feb 28, 2022 |
| FY2021 | Dec 31, 2020 | $8.0K | Feb 28, 2022 |
| FY2021 | Dec 31, 2019 | $136.0K | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $2.0K | Mar 15, 2021 |
| FY2018 | Dec 31, 2017 | $10.0K | Mar 1, 2019 |
| FY2015 | Dec 31, 2015 | $287.0K | Mar 25, 2016 |
| FY2015 | Dec 31, 2014 | $137.0K | Mar 25, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $30.46M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $89.55M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $72.15M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $240.75M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $122.82M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $114.37M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $111.56M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $75.10M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $104.10M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $36.83M | Mar 24, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $58.37M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $63.02M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $107.02M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $69.04M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $132.05M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $141.07M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $67.35M | Mar 16, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $26.53M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | ($157.07M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $171.71M | Feb 28, 2023 |
| FY2022 | Dec 31, 2020 | ($9.23M) | Feb 28, 2023 |
| FY2022 | Dec 31, 2019 | ($26.70M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | $44.21M | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | $18.03M | Mar 15, 2021 |
| FY2019 | Dec 31, 2016 | $38.68M | Mar 16, 2020 |
| FY2018 | Dec 31, 2015 | $18.94M | Mar 1, 2019 |
| FY2017 | Dec 31, 2014 | $36.83M | Apr 2, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $0 | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | $13.10M | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | $13.06M | Feb 28, 2023 |
| FY2021 | Sep 30, 2021 | $13.10M | Feb 28, 2022 |
| FY2021 | Dec 31, 2020 | $13.06M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $13.06M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $13.06M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $13.06M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $16.86M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Mar 24, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($305.58M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($245.10M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($158.22M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($316.26M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($315.92M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($293.52M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($186.02M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($152.33M) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | ($123.31M) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | ($125.20M) | Mar 24, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $17.91M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $77.61M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $24.19M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $162.64M | Feb 28, 2023 |
| FY2022 | Dec 31, 2020 | $52.39M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $48.12M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $50.42M | Mar 15, 2021 |
| FY2018 | Dec 31, 2017 | $14.68M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $25.34M | Apr 2, 2018 |
| FY2017 | Dec 31, 2015 | $36.08M | Apr 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (1) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | (2) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (28) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Feb 28, 2023 |
| FY2022 | Dec 31, 2020 | 0 | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 28, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | (1) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 2, 2018 |
| FY2017 | Sep 30, 2016 | 0 | Apr 2, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (1) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | (2) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (28) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Feb 28, 2023 |
| FY2022 | Dec 31, 2020 | 0 | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 28, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | (1) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 2, 2018 |
| FY2017 | Sep 30, 2016 | 0 | Apr 2, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 41.75M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | 40.61M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 2.22M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 199.46M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 140.45M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 106.80M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | 77.46M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 34.70M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 24.53M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | 19.62M | Mar 24, 2017 |